Detalles de la búsqueda
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081848
2.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
; 22(4): 476-488, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721561
3.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33460574
4.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33828257
5.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109233
6.
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.
Anticancer Drugs
; 30(8): 866-872, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31305270
7.
Genomic hotspots but few recurrent fusion genes in breast cancer.
Genes Chromosomes Cancer
; 57(7): 331-338, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29436103
8.
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Breast Cancer Res Treat
; 168(3): 631-638, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29280043
9.
The footprint of the ageing stroma in older patients with breast cancer.
Breast Cancer Res
; 19(1): 78, 2017 Jul 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28673354
10.
Uncovering the genomic heterogeneity of multifocal breast cancer.
J Pathol
; 236(4): 457-66, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25850943
11.
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
BMC Med
; 13: 177, 2015 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26234940
12.
No significant viral transcription detected in whole breast cancer transcriptomes.
BMC Cancer
; 15: 147, 2015 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25884932
13.
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
BMC Genomics
; 15: 1008, 2014 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25412710
14.
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
Lancet Oncol
; 13(6): e240-8, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22652232
15.
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Curr Opin Oncol
; 24(6): 623-34, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22960556
16.
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
Lancet Oncol
; 12(12): 1162-8, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21684810
17.
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.
J Natl Cancer Inst
; 114(3): 467-470, 2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33787900
18.
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Eur J Cancer
; 166: 219-228, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313167
19.
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
J Natl Cancer Inst
; 114(8): 1117-1126, 2022 08 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35512402
20.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172272